Items where authors include "Allanore, Y"

Article

Hoffmann-Vold, A-M, Brunborg, C, Airò, P et al. (13 more authors) (2023) Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research. Chest, 163 (3). pp. 586-598. ISSN 0012-3692

Bellando-Randone, S, Del Galdo, F orcid.org/0000-0002-8528-2283, Lepri, G et al. (13 more authors) (2021) Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). The Lancet Rheumatology, 3 (12). e834-e843. ISSN 2665-9913

Allanore, Y, Bozzi, S, Terlinden, A et al. (14 more authors) (2020) Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research and Therapy, 22. 257. ISSN 1478-6354

Hughes, M, Alcacer-Pitarch, B orcid.org/0000-0002-2208-444X, Allanore, Y et al. (7 more authors) (2020) Digital ulcers: should debridement be a standard of care in systemic sclerosis? The Lancet Rheumatology, 2 (5). e302-e307. ISSN 2665-9913

Blagojevic, J, Bellando-Randone, S, Abignano, G et al. (22 more authors) (2019) Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey. Arthritis Research & Therapy, 21 (1). 35. ISSN 1478-6354

Sobanski, V, Giovannelli, J, Allanore, Y et al. (10 more authors) (2019) Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 71 (9). pp. 1553-1570. ISSN 2326-5191

Jaworski, J, Matucci-Cerinic, M, Schulze-Koops, H et al. (6 more authors) (2019) Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Research and Therapy, 21 (1). 130. ISSN 1478-6354

Abignano, G, Blagojevic, J, Bissell, L-A orcid.org/0000-0002-2789-4652 et al. (16 more authors) (2019) European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology, 58 (2). key271. pp. 254-259. ISSN 1462-0324

Jaeger, VK, Valentini, G, Hachulla, E et al. (22 more authors) (2018) Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 70 (11). pp. 1829-1834. ISSN 2326-5191

Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A et al. (8 more authors) (2018) Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open, 4 (2). e000757. ISSN 2056-5933

Ndosi, M orcid.org/0000-0002-7764-3173, Alcacer-Pitarch, B, Allanore, Y et al. (14 more authors) (2018) Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. Annals of the Rheumatic Diseases, 77 (7). pp. 1032-1038. ISSN 0003-4967

Jaeger, VK, Distler, O, Maurer, B et al. (37 more authors) (2018) Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 57 (3). pp. 441-450. ISSN 1462-0324

Carmona, DF, Vaglio, A, Mackie, SL orcid.org/0000-0003-2483-5873 et al. (53 more authors) (2017) A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis. American Journal of Human Genetics, 100 (1). pp. 64-74. ISSN 0002-9297

Jaeger, VK, Wirz, EG, Allanore, Y et al. (96 more authors) (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLOS ONE, 11 (10). e0163894.

Wirz, EG, Jaeger, VK, Allanore, Y et al. (15 more authors) (2015) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 75 (7). pp. 1285-1292. ISSN 0003-4967

Proceedings Paper

Kavanaugh, A, Matucci-Cerinic, M, Schulze-Koops, H et al. (4 more authors) (2018) Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .